Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

Adam Brufsky, W. Graydon Harker, J. Thaddeus Beck, Robert Carroll, Elizabeth Tan-Chiu, Christopher Seidler, John Hohneker, Leo Lacerna, Stephanie Petrone, Edith A. Perez

Research output: Contribution to journalArticle

270 Scopus citations

Abstract

Purpose: Treatment with aromatase inhibitors decreases bone mineral density (BMD) and may increase the risk of fractures in postmenopausal women with early-stage breast cancer. The addition of zoledronic acid to adjuvant letrozole therapy may protect against bone loss. Patients and Methods: Patients receiving adjuvant letrozole were randomly assigned to receive either upfront or delayed-start zoledronic acid (4 mg intravenously every 6 months). The delayed group received zoledronic acid when lumbar spine (LS) or total hip (TH) T score decreased to less than -2.0 or when a nontraumatic fracture occurred. The primary end point of this study was to compare the change in LS BMD at month 12 between the groups. Secondary end points included change in TH BMD and changes in serum bone turnover markers at month 12. Results: The upfront and delayed groups each included 301 patients. At month 12, LS BMD was 4.4% higher in the upfront group than in the delayed group (95% CI, 3.7% to 5.0%; P < .0001), and TH BMD was 3.3% higher (95% CI, 2.8% to 3.8%; P < .0001). In the upfront group, mean serum N-telopeptide and bone-specific alkaline phosphatase concentrations decreased by 15.1% (P < .0001) and 8.8% (P = .0006), respectively, at month 12, whereas concentrations increased significantly in the delayed group by 19.9% (P = .013) and 24.3% (P < .0001), respectively. Conclusion: With 1 year of follow-up, results of the primary end point of the Zometa-Femara Adjuvant Synergy Trial (Z-FAST) indicate that upfront zoledronic acid therapy prevents bone loss in the LS in postmenopausal women receiving adjuvant letrozole for early-stage breast cancer.

Original languageEnglish (US)
Pages (from-to)829-836
Number of pages8
JournalJournal of Clinical Oncology
Volume25
Issue number7
DOIs
StatePublished - Mar 1 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Brufsky, A., Harker, W. G., Beck, J. T., Carroll, R., Tan-Chiu, E., Seidler, C., Hohneker, J., Lacerna, L., Petrone, S., & Perez, E. A. (2007). Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology, 25(7), 829-836. https://doi.org/10.1200/JCO.2005.05.3744